Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo.
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Interleukin (IL) 4 is a multifunctional T cell-derived cytokine that inhibits cytokine production and certain effector functions in human monocytes, while enhancing others. We show that IL-4 may contribute to the downregulation and resolution of an inflammatory response by selectively promoting expression of the IL-1 receptor antagonist (IL-1ra) that blocks the action of IL-1. IL-1ra specifically binds to the IL-1 receptor without initiating signal transduction. Peripheral blood monocytes obtained from cancer patients, before and immediately after a regimen of IL-4 immunotherapy, were examined for IL-1ra gene expression. After IL-4 therapy, monocytes from the patients showed a marked increase in IL-1ra mRNA. This selective induction of IL-1ra mRNA in circulating monocytes was reflected by significantly enhanced serum levels of IL-1ra (p < 0.01) during IL-4 therapy, which declined after IL-4 treatment. In vitro analysis of IL-4 regulation of monocytes from normal individuals revealed a dose-dependent induction of IL-1ra mRNA within 2-4 h after stimulation without a concomitant effect on the expression of IL-1 mRNA. Increased IL-1ra mRNA was not due to RNA stabilization, but occurred at the level of transcription. In the presence of LPS, IL-4 not only augmented IL-1ra levels, but markedly inhibited LPS-induced IL-1 mRNA expression. The selective upregulation of IL-1ra by resting or activated monocytes, coupled with inhibition of IL-1 production by activated monocytes, as we demonstrate both in vitro and in vivo, suggests that IL-4 may prove clinically useful as a systemic antiinflammatory agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122 · cited 1×
“of PGE2 and collagenase by fibroblasts, synoviocytes, and chondrocytes in culture (34, 35).”
BackgroundCarter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601 · cited 2×
“, Keene, NH) and prehybridized at 42~ for at least 4 h before hybridization at 42~ with 32p-labeled human Ibl~ (22), IL-lra (18), (generously provided by Dr.”
Background
Cited by
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Ghoreschi, K., Thomas, P., Breit, S., Dugas, M., Mailhammer, R., van Eden, W., van der Zee, R., Biedermann, T., Prinz, J., Mack, M., et al. (2003) · Nature Medicine · doi:10.1038/nm804 · Cited by 453
BOGDAN, C., & NATHAN, C. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35934.x · Cited by 384
IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease
Röcken, M., Racke, M., & Shevach, E. M. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80556-1 · Cited by 264
Pro-and Anti-inflammatory Cytokines in Rheumatoid Arthritis
Isomäki, P., & Punnonen, J. (1997) · Annals of Medicine · doi:10.3109/07853899709007474 · Cited by 260
A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis
Brück, J., Dringen, R., Amasuno, A., Pau‐Charles, I., & Ghoreschi, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13548 · Cited by 128
Metadata
- Authors
- Wong, H. L., Costa, G. L., Lotze, M. T., & Wahl, S. M.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1993-03-01
- Volume
- 177
- Issue
- 3
- Pages
- 775-781
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2138811709
- Cited by
- 88
- References
- 2
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.